Literature DB >> 12675906

Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.

Ann D Cohen1, Jennifer L Tillerson, Amanda D Smith, Timothy Schallert, Michael J Zigmond.   

Abstract

Unilateral administration of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB) causes a loss of dopamine (DA) in the ipsilateral striatum and contralateral motor deficits. However, if a cast is placed on the ipsilateral limb during the first 7 days following 6-OHDA infusion, forcing the animal to use its contralateral limb, both the behavioral and neurochemical deficits are reduced. Here, we examine the effect of forced reliance on a forelimb during the 7 days prior to ipsilateral infusion of 6-OHDA on the deficits characteristic of this lesion model. Casted animals displayed no behavioral asymmetries as measured 14-28 days postlesion and a marked attenuation in the loss of striatal DA and its metabolites at 30 days. In addition, animals receiving a unilateral cast alone had an increase in glial cell-line derived neurotrophic factor (GDNF) protein in the striatum corresponding to the overused limb. GDNF increased within 1 day after the onset of casting, peaked at 3 days, and returned to baseline within 7 days. These results suggest that preinjury forced limb-use can prevent the behavioral and neurochemical deficits to the subsequent administration of 6-OHDA and that this may be due in part to neuroprotective effects of GDNF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675906     DOI: 10.1046/j.1471-4159.2003.01657.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  73 in total

Review 1.  Motor enrichment and the induction of plasticity before or after brain injury.

Authors:  Jeffrey A Kleim; Theresa A Jones; Timothy Schallert
Journal:  Neurochem Res       Date:  2003-11       Impact factor: 3.996

2.  Physical exercise attenuates MPTP-induced deficits in mice.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2010-03-19       Impact factor: 3.911

Review 3.  Targeted exercise therapy for voice and swallow in persons with Parkinson's disease.

Authors:  John A Russell; Michelle R Ciucci; Nadine P Connor; Timothy Schallert
Journal:  Brain Res       Date:  2010-03-15       Impact factor: 3.252

4.  Exercise protects against MPTP-induced neurotoxicity in mice.

Authors:  Kimberly M Gerecke; Yun Jiao; Amar Pani; Vishwajeeth Pagala; Richard J Smeyne
Journal:  Brain Res       Date:  2010-01-29       Impact factor: 3.252

5.  Delayed exercise-induced functional and neurochemical partial restoration following MPTP.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2011-08-10       Impact factor: 3.911

6.  Cueing training in persons with Parkinson's disease.

Authors:  M A Hirsch; F M Hammond
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02       Impact factor: 10.154

Review 7.  How might physical activity benefit patients with Parkinson disease?

Authors:  Arlène D Speelman; Bart P van de Warrenburg; Marlies van Nimwegen; Giselle M Petzinger; Marten Munneke; Bastiaan R Bloem
Journal:  Nat Rev Neurol       Date:  2011-07-12       Impact factor: 42.937

8.  Recreational physical activity and risk of Parkinson's disease.

Authors:  Evan L Thacker; Honglei Chen; Alpa V Patel; Marjorie L McCullough; Eugenia E Calle; Michael J Thun; Michael A Schwarzschild; Alberto Ascherio
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

9.  Changes in brain functional activation during resting and locomotor states after unilateral nigrostriatal damage in rats.

Authors:  J Yang; T R Sadler; T K Givrad; J-M I Maarek; D P Holschneider
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

10.  Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats.

Authors:  Elissa M Strome; Athanasios P Zis; Doris J Doudet
Journal:  J Psychiatry Neurosci       Date:  2007-05       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.